Low-Dose r-ATG vs Basiliximab in Low-Risk Living-Donor Kidney Transplantation: Outcomes in Acute Rejection, Graft Function, and Infections

21 October 2025 : Original article

Nam Ho

^{ABDEF 1}, Thu Thi Nguyen^{BCDF 1}, Nam Van Do^{BCD 1}, Chi Tam Nguyen

^{BEF 1}, Su Xuan Hoang^{DEF 2}, Khanh Vo Ngoc Hoang^{BEF 3}, Trung Dinh Ngo^{ABDEF 1*}

DOI: 10.12659/AOT.949942

Ann Transplant 2025; 30:e949942

Authors information Article notes Copyright and License information

Introduction Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 3 Risk analysis of acute rejection.

	Univariate HR (95% CI)	P value	Multivariate HR (95% CI)	P value
Sex	0.67 (0.32–1.41)	0.296
Age	0.65 (0.19–2.23)	0.495
Introduction r-ATG/Basiliximab	0.87 (0.29–2.61)	0.827	0.61 (0.20–1.86)	0.383
BMI	1.01 (0.86–1.21)	0.826
Dialysis duration	0.98 (0.95–1.01)	0.321
HLA I-MM	2.10 (0.87–5.09)	0.1	3.06 (1.25–7.52)	0.014
HLA II-MM	3.38 (1.34–9.95)	0.007	5.59 (1.95–17.75)	0.002
CMV-status	0.20 (0.05–0.88)	0.33
WIT	1.00 (0.97–1.03)	0.857
CIT	0.98 (0.95–1.03)	0.557
r-ATG – rabbit anti-thymocyte globulin; BSX – basiliximab; BMI – body mass index; CMV – Cytomegalovirus; HLA – human leukocyte antigen; MM – mismatch; WIT – warm ischemia time; CIT – cold ischemia time; BPAR – biopsy-proven acute rejection.

Back to the Article